Analyst Research

Report Title Price
Provider: GlobalData
Provider: Edison Investment Research
Provider: Reuters Investment Profile
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Morphosys AG to receive orphan drug designation from FDA and EMA on MOR208 program

Tuesday, 20 May 2014 01:31am EDT 

Morphosys AG:Announces that the Food & Drug Association (FDA) has granted orphan drug designation to MOR208, MorphoSys' humanized Fc engineered monoclonal antibody against CD19, for the treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL).The company has received a positive opinion from the European Medicines Agency (EMA) for an orphan medicinal product application for MOR208 in these indications. 

Company Quote

0.89 +1.31%
22 May 2015